Inventor · Boulder, CO, US

Christopher Mayne

12Patents
3h-index
48Co-inventors
49Inventor score

Filing activity: Dec 18, 2019 → Nov 28, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US11149007B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith Chemistry; Metallurgy 10 Active
US11325889B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith Chemistry; Metallurgy 9 Active
US11634407B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Human Necessities 4 Active
US11560371B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Chemistry; Metallurgy 2 Active
US11739075B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Human Necessities 2 Active
US11873295B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease Chemistry; Metallurgy 1 Active
US11873283B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith Chemistry; Metallurgy 1 Active
US11649227B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease Chemistry; Metallurgy 0 Active
US12404241B2 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith Chemistry; Metallurgy 0 Active
US12227490B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Human Necessities 0 Active
US12103920B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Human Necessities 0 Active
US11878970B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.